For best viewing of the website please use Mozilla Firefox or Google Chrome.
Citation: Haoru Dong, Xinhua Shu, Qiang Xu, Chen Zhu, Andreas M. Kaufmann, Zhi-Ming Zheng, Andreas E. Albers, Xu Qian. Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care [J].VIROLOGICA SINICA, 2021, 36(6) : 1284-1302.  http://dx.doi.org/10.1007/s12250-021-00413-8

Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care

  • Corresponding author: Xu Qian, Qian_michelle2014@163.com, ORCID: http://orcid.org/0000-0003-0629-4460
  • Received Date: 21 January 2021
    Accepted Date: 18 May 2021
    Published Date: 21 June 2021
    Available online: 01 December 2021
  • Human papillomavirus (HPV) infection identified as a definitive human carcinogen is increasingly being recognized for its role in carcinogenesis of human cancers. Up to 38%–80% of head and neck squamous cell carcinoma (HNSCC) in oropharyngeal location (OPSCC) and nearly all cervical cancers contain the HPV genome which is implicated in causing cancer through its oncoproteins E6 and E7. Given by the biologically distinct HPV-related OPSCC and a more favorable prognosis compared to HPV-negative tumors, clinical trials on de-escalation treatment strategies for these patients have been studied. It is therefore raised the questions for the patient stratification if treatment de-escalation is feasible. Moreover, understanding the crosstalk of HPV-mediated malignancy and immunity with clinical insights from the proportional response rate to immune checkpoint blockade treatments in patients with HNSCC is of importance to substantially improve the treatment efficacy. This review discusses the biology of HPV-related HNSCC as well as successful clinically findings with promising candidates in the pipeline for future directions. With the advent of various sequencing technologies, further biomolecules associated with HPV-related HNSCC progression are currently being identified to be used as potential biomarkers or targets for clinical decisions throughout the continuum of cancer care.


  • 加载中
    1. Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Knoblock DM, Bauml JM, Weinstein GS, Lin A, Boyer J, Sakata L, Tan S, Anton A, Dickerson K, Mangrolia D, Vang R, Dallas M, Oyola S, Duff S, Esser M, Kumar R, Weiner D, Csiki I, Bagarazzi ML (2019) Immunotherapy targeting HPV16/18 generates potent immune responses in HPV-associated head and neck cancer. Clin Cancer Res 25: 110–124
        doi: 10.1158/1078-0432.CCR-18-1763

    2. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, Zhang N, El-Naggar AK, Jasser SA, Weinstein JN, Treviño L, Drummond JA, Muzny DM, Wu Y, Wood LD, Hruban RH, Westra WH, Koch WM, Califano JA, Gibbs RA, Sidransky D, Vogelstein B, Velculescu VE, Papadopoulos N, Wheeler DA, Kinzler KW, Myers JN (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154–1157
        doi: 10.1126/science.1206923

    3. Ajiro M, Jia R, Zhang L, Liu X, Zheng ZM (2012) Intron definition and a branch site adenosine at nt 385 control RNA splicing of HPV16 E6*I and E7 expression. PLoS ONE 7: e46412
        doi: 10.1371/journal.pone.0046412

    4. Ajiro M, Tang S, Doorbar J, Zheng ZM (2016) Serine/Arginine-rich splicing factor 3 and heterogeneous nuclear ribonucleoprotein A1 regulate alternative RNA splicing and gene expression of human papillomavirus 18 through two functionally distinguishable cis elements. J Virol 90: 9138–9152
        doi: 10.1128/JVI.00965-16

    5. Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, Rocco JW, Teknos TN, Kumar B, Wangsa D, He D, Ried T, Symer DE, Gillison ML (2014) Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res 24: 185–199
        doi: 10.1101/gr.164806.113

    6. Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C, Gooding W, Whiteside TL, Ferrone S, DeLeo A, Ferris RL (2005) Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 65: 11146–11155
        doi: 10.1158/0008-5472.CAN-05-0772

    7. Albers AE, Qian X, Kaufmann AM, Coordes A (2017) Meta analysis: HPV and p16 pattern determines survival in patients with HNSCC and identifies potential new biologic subtype. Sci Rep 7: 16715
        doi: 10.1038/s41598-017-16918-w

    8. Albers AE, Strauss L, Liao T, Hoffmann TK, Kaufmann AM (2010) T cell-tumor interaction directs the development of immunotherapies in head and neck cancer. Clin Dev Immunol 2010: 236378
        doi: 10.1155/2010/236378

    9. Altenhofen B, DeWees TA, Ahn JW, Yeat NC, Goddu S, Chen I, Lewis JS Jr, Thorstad WL, Chole RA (2017) Human papilloma virus load and PD-1/PD-L1, CD8(+) and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy. Oncoimmunology 6: e1288331
        doi: 10.1080/2162402X.2017.1288331

    10. Balermpas P, Martin D, Wieland U, Rave-Frank M, Strebhardt K, Rödel C, Fokas E, Rödel F (2017) Human papilloma virus load and PD-1/PD-L1, CD8(+) and FOXP3 in anal cancer patients treated with chemoradiotherapy: rationale for immunotherapy. Oncoimmunology 6: e1288331
        doi: 10.1080/2162402X.2017.1288331

    11. Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R (2017) Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase Ⅱ study. J Clin Oncol 35: 1542–1549
        doi: 10.1200/JCO.2016.70.1524

    12. Beachler DC, Abraham AG, Silverberg MJ, Jing Y, Fakhry C, Gill MJ, Dubrow R, Kitahata MM, Klein MB, Burchell AN, Korthuis PT, Moore RD, D'Souza G (2014) Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. Oral Oncol 50: 1169–1176
        doi: 10.1016/j.oraloncology.2014.09.011

    13. Bhatt KH, Neller MA, Srihari S, Crooks P, Lekieffre L, Aftab BT, Liu H, Smith C, Kenny L, Porceddu S, Khanna R (2020) Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients. J Exp Med 217: e20200389
        doi: 10.1084/jem.20200389

    14. Bigelow EO, Seiwert TY, Fakhry C (2020) Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions. Oral Oncol 105: 104652
        doi: 10.1016/j.oraloncology.2020.104652

    15. Boscolo-Rizzo P, Del Mistro A, Bussu F, Lupato V, Baboci L, Almadori G (2013) New insights into human papillomavirus-associated head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital 33: 77–87

    16. Boscolo-Rizzo P, Furlan C, Lupato V, Polesel J, Fratta E (2017) Novel insights into epigenetic drivers of oropharyngeal squamous cell carcinoma: role of HPV and lifestyle factors. Clin Epigenetics 9: 124
        doi: 10.1186/s13148-017-0424-5

    17. Böttinger P, Schreiber K, Hyjek E, Krausz T, Spiotto MT, Steiner M, Idel C, Booras H, Beck-Engeser G, Riederer J, Willimsky G, Wolf SP, Karrison T, Jensen E, Weichselbaum RR, Nakamura Y, Yew PY, Lambert PF, Kurita T, Kiyotani K, Leisegang M, Schreiber H (2020) Cooperation of genes in HPV16 E6/E7-dependent cervicovaginal carcinogenesis trackable by endoscopy and independent of exogenous estrogens or carcinogens. Carcinogenesis 41: 1605–1615
        doi: 10.1093/carcin/bgaa027

    18. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V (2009) A review of human carcinogens–Part B: biological agents. Lancet Oncol 10: 321–322
        doi: 10.1016/S1470-2045(09)70096-8

    19. Božinović K, Sabol I, Rakušić Z, Jakovčević A, Šekerija M, Lukinović J, Prgomet D, Grce M (2019) HPV-driven oropharyngeal squamous cell cancer in Croatia - Demography and survival. PLoS ONE 14: e0211577
        doi: 10.1371/journal.pone.0211577

    20. Brant AC, Majerciak V, Moreira MAM, Zheng ZM (2019) HPV18 utilizes two alternative branch sites for E6*I splicing to produce E7 protein. Virol Sin 34: 211–221
        doi: 10.1007/s12250-019-00098-0

    21. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394–424
        doi: 10.3322/caac.21492

    22. Broutian TR, Jiang B, Li J, Akagi K, Gui S, Zhou Z, Xiao W, Symer DE, Gillison ML (2020) Human papillomavirus insertions identify the PIM family of serine/threonine kinases as targetable driver genes in head and neck squamous cell carcinoma. Cancer Lett 476: 23–33
        doi: 10.1016/j.canlet.2020.01.012

    23. Buexm LA, Soares-Lima SC, Brennan P, Fernandes PV (2020) Hpv impact on oropharyngeal cancer patients treated at the largest cancer center from Brazil. Cancer Lett 477: 70–75
        doi: 10.1016/j.canlet.2020.02.023

    24. Burley M, Roberts S, Parish JL (2020) Epigenetic regulation of human papillomavirus transcription in the productive virus life cycle. Semin Immunopathol 42: 159–171
        doi: 10.1007/s00281-019-00773-0

    25. Burns MB, Temiz NA, Harris RS (2013) Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 45: 977–983
        doi: 10.1038/ng.2701

    26. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, De Castro G, Psyrri Jr A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394: 1915–1928
        doi: 10.1016/S0140-6736(19)32591-7

    27. Castellsagué X, Alemany L, Quer M, Halec G, Quirós B, Tous S, Clavero O, Alòs L, Biegner T, Szafarowski T, Alejo M, Holzinger D, Cadena E, Claros E, Hall G, Laco J, Poljak M, Benevolo M, Kasamatsu E, Mehanna H, Ndiaye C, Guimerà N, Lloveras B, León X, Ruiz-Cabezas JC, Alvarado-Cabrero I, Kang CS, Oh JK, Garcia-Rojo M, Iljazovic E, Ajayi OF, Duarte F, Nessa A, Tinoco L, Duran-Padilla MA, Pirog EC, Viarheichyk H, Morales H, Costes V, Félix A, Germar MJ, Mena M, Ruacan A, Jain A, Mehrotra R, Goodman MT, Lombardi LE, Ferrera A, Malami S, Albanesi EI, Dabed P, Molina C, López-Revilla R, Mandys V, González ME, Velasco J, Bravo IG, Quint W, Pawlita M, Muñoz N, de Sanjosé S, Xavier Bosch F (2016) HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J Natl Cancer Inst 108: 403
        doi: 10.1093/jnci/djv403

    28. Chargi N, Bril SI, Swartz JE, Wegner I, Willems SM, de Bree R (2020) Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma. Oral Oncol 101: 104519
        doi: 10.1016/j.oraloncology.2019.104519

    29. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS, Bray F, Gillison ML (2013) Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 31: 4550–4559
        doi: 10.1200/JCO.2013.50.3870

    30. Chen TC, Wu CT, Ko JY, Yang TL, Lou PJ, Wang CP, Chang YL (2020) Clinical characteristics and treatment outcome of oropharyngeal squamous cell carcinoma in an endemic betel quid region. Sci Rep 10: 526
        doi: 10.1038/s41598-019-57177-1

    31. Chor JS, Vlantis AC, Chow TL, Fung SC, Ng FY, Lau CH, Chan AB, Ho LC, Kwong WH, Fung MN, Lam EW, Mak KL, Lam HC, Kok AS, Ho WC, Yeung AC, Chan PK (2016) The role of human papillomavirus in head and neck squamous cell carcinoma: a case control study on a southern Chinese population. J Med Virol 88: 877–887
        doi: 10.1002/jmv.24405

    32. Christensen JT, Grønhøj C, Zamani M, Brask J, Kjær EKR, Lajer H, von Buchwald C (2019) Association between oropharyngeal cancers with known HPV and p16 status and cervical intraepithelial neoplasia: a Danish population-based study. Acta Oncol 58: 267–272
        doi: 10.1080/0284186X.2018.1546059

    33. Chuang SC, Scelo G, Tonita JM, Tamaro S, Jonasson JG, Kliewer EV, Hemminki K, Weiderpass E, Pukkala E, Tracey E, Friis S, Pompe-Kirn V, Brewster DH, Martos C, Chia KS, Boffetta P, Brennan P, Hashibe M (2008) Risk of second primary cancer among patients with head and neck cancers: a pooled analysis of 13 cancer registries. Int J Cancer 123: 2390–2396
        doi: 10.1002/ijc.23798

    34. Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, Oesterreich S, Chen W, Lafyatis R, Bruno TC, Ferris RL, Vignali DAA (2020) Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. Immunity 52: 183-199. e189
        doi: 10.1016/j.immuni.2019.11.014

    35. Colevas AD, Bahleda R, Braiteh F, Balmanoukian A, Brana I, Chau NG, Sarkar I, Molinero L, Grossman W, Kabbinavar F, Fassò M, O'Hear C, Powderly J (2018) Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Ann Oncol 29: 2247–2253
        doi: 10.1093/annonc/mdy411

    36. Conner KL, Shaik AN, Ekinci E, Kim S, Ruterbusch JJ, Cote ML, Patrick SM (2020) HPV induction of APOBEC3 enzymes mediate overall survival and response to cisplatin in head and neck cancer. DNA Repair (amst) 87: 102802
        doi: 10.1016/j.dnarep.2020.102802

    37. Contreras-Paredes A, De la Cruz-Hernández E, Martínez-Ramírez I, Dueñas-González A, Lizano M (2009) E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway. Virology 383: 78–85
        doi: 10.1016/j.virol.2008.09.040

    38. Cramer JD, Burtness B, Ferris RL (2019) Immunotherapy for head and neck cancer: Recent advances and future directions. Oral Oncol 99: 104460
        doi: 10.1016/j.oraloncology.2019.104460

    39. Cui T, Enroth S, Ameur A, Gustavsson I, Lindquist D, Gyllensten U (2019) Invasive cervical tumors with high and low HPV titer represent molecular subgroups with different disease etiology. Carcinogenesis 40: 269–278
        doi: 10.1093/carcin/bgy183

    40. De Cicco R, de Melo MR, Nicolau UR, Pinto CAL, Villa LL, Kowalski LP (2020) Impact of human papillomavirus status on survival and recurrence in a geographic region with a low prevalence of HPV-related cancer: a retrospective cohort study. Head Neck 42: 93–102
        doi: 10.1002/hed.25985

    41. De Felice F, Bird T, Michaelidou A, Thavaraj S, Odell E, Sandison A, Hall G, Morgan P, Lyons A, Cascarini L, Fry A, Oakley R, Simo R, Jeannon JP, Lei M, Guerrero Urbano T (2020) Radical (chemo) radiotherapy in oropharyngeal squamous cell carcinoma: comparison of TNM 7th and 8th staging systems. Radiother Oncol 145: 146–153
        doi: 10.1016/j.radonc.2019.12.021

    42. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM (2020) Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 8: e180–e190
        doi: 10.1016/S2214-109X(19)30488-7

    43. Dickstein DR, Egerman MA, Bui AH, Doucette JT, Sharma S, Liu J, Gupta V, Miles BA, Genden E, Westra WH, Misiukiewicz K, Posner MR, Bakst RL (2020) A new face of the HPV epidemic: oropharyngeal cancer in the elderly. Oral Oncol 109: 104687
        doi: 10.1016/j.oraloncology.2020.104687

    44. Dsouza G, Carey TE, William WN Jr, Nguyen ML, Ko EC, Jt R, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RL (2014) Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr 65: 603–610
        doi: 10.1097/QAI.0000000000000083

    45. Eckhardt M, Zhang W, Gross AM, Von Dollen J, Johnson JR, Franks-Skiba KE, Swaney DL, Johnson TL, Jang GM, Shah PS, Brand TM, Archambault J, Kreisberg JF, Grandis JR, Ideker T, Krogan NJ (2018) Multiple routes to oncogenesis are promoted by the human papillomavirus-host protein network. Cancer Discov 8: 1474–1489
        doi: 10.1158/2159-8290.CD-17-1018

    46. Elhalawani H, Mohamed ASR, Elgohari B, Lin TA, Sikora AG, Lai SY, Abusaif A, Phan J, Morrison WH, Gunn GB, Rosenthal DI, Garden AS, Fuller CD, Sandulache VC (2020) Tobacco exposure as a major modifier of oncologic outcomes in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma. BMC Cancer 20: 912
        doi: 10.1186/s12885-020-07427-7

    47. Facompre ND, Rajagopalan P, Sahu V, Pearson AT, Montone KT, James CD, Gleber-Netto FO, Weinstein GS, Jalaly J, Lin A, Rustgi AK, Nakagawa H, Califano JA, Pickering CR, White EA, Windle BE, Morgan IM, Cohen RB, Gimotty PA, Basu D (2020) Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models. Int J Cancer 147: 3236–3249
        doi: 10.1002/ijc.33125

    48. Fakhry C, Lacchetti C, Rooper LM, Jordan RC, Rischin D, Sturgis EM, Bell D, Lingen MW, Harichand-Herdt S, Thibo J, Zevallos J, Perez-Ordonez B (2018) Human papillomavirus testing in head and neck carcinomas: ASCO clinical practice guideline endorsement of the college of american pathologists guideline. J Clin Oncol 36: 3152–3161
        doi: 10.1200/JCO.18.00684

    49. Fakhry C, Waterboer T, Westra WH, Rooper LM, Windon M, Troy T, Koch W, Gourin CG, Bender N, Yavvari S, Kiess AP, Miles BA, Ryan WR, Ha PK, Eisele DW, D'Souza G (2020) Distinct biomarker and behavioral profiles of human papillomavirus-related oropharynx cancer patients by age. Oral Oncol 101: 104522
        doi: 10.1016/j.oraloncology.2019.104522

    50. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML (2018) Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81: 45–51
        doi: 10.1016/j.oraloncology.2018.04.008

    51. Freitag J, Wald T, Kuhnt T, Gradistanac T, Kolb M, Dietz A, Wiegand S, Wichmann G (2020) Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma. Cancer 126: 1856–1872
        doi: 10.1002/cncr.32667

    52. Galvis MM, Borges GA, Oliveira TB, Toledo IP, Castilho RM, Guerra ENS, Kowalski LP, Squarize CH (2020) Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 150: 102966
        doi: 10.1016/j.critrevonc.2020.102966

    53. Gameiro SF, Ghasemi F, Barrett JW, Koropatnick J, Nichols AC, Mymryk JS, Maleki Vareki S (2018) Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy. Oncoimmunology 7: e1498439
        doi: 10.1080/2162402X.2018.1498439

    54. Gameiro SF, Ghasemi F, Barrett JW, Nichols AC, Mymryk JS (2019) High level expression of MHC-Ⅱ in HPV+ head and neck cancers suggests that tumor epithelial cells serve an important role as accessory antigen presenting cells. Cancers (basel) 11: 1129
        doi: 10.3390/cancers11081129

    55. Gandhapudi SK, Ward M, Bush JPC, Bedu-Addo F, Conn G, Woodward JG (2019) Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a type Ⅰ IFN response. J Immunol 202: 3524–3536
        doi: 10.4049/jimmunol.1801634

    56. García-Escudero R, Segrelles C, Dueñas M, Pombo M, Ballestín C, Alonso-Riaño M, Nenclares P, Álvarez-Rodríguez R, Sánchez-Aniceto G, Ruíz-Alonso A, López-Cedrún JL, Paramio JM, Lorz C (2018) Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway. Oral Oncol 79: 55–63
        doi: 10.1016/j.oraloncology.2018.02.014

    57. Gaździcka J, Gołąbek K, Strzelczyk JK, Ostrowska Z (2020) Epigenetic modifications in head and neck cancer. Biochem Genet 58: 213–244
        doi: 10.1007/s10528-019-09941-1

    58. Gazzaz MJ, Jeffery C, O'Connell D, Harris J, Seikaly H, Biron V (2019) Association of human papillomavirus related squamous cell carcinomas of the oropharynx and cervix. Papillomavirus Res 8: 100188
        doi: 10.1016/j.pvr.2019.100188

    59. Gillison ML, Akagi K, Xiao W, Jiang B, Pickard RKL, Li J, Swanson BJ, Agrawal AD, Zucker M, Stache-Crain B, Emde AK, Geiger HM, Robine N, Coombes KR, Symer DE (2019a) Human papillomavirus and the landscape of secondary genetic alterations in oral cancers. Genome Res 29: 1–17
        doi: 10.1101/gr.241141.118

    60. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C (2015) Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol 33: 3235–3242
        doi: 10.1200/JCO.2015.61.6995

    61. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Jordan RCK, Zhao W, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT (2019b) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393: 40–50
        doi: 10.1016/S0140-6736(18)32779-X

    62. Girardi FM, Wagner VP, Martins MD, Abentroth AL, Hauth LA (2020) Prevalence of p16 expression in oropharyngeal squamous cell carcinoma in southern Brazil. Oral Surg Oral Med Oral Pathol Oral Radiol. https://doi.org/10.1016/j.oooo.2020.08.021
        doi: 10.1016/j.oooo.2020.08.021

    63. Grønhøj C, Jensen JS, Wagner S, Dehlendorff C, Friborg J, Andersen E, Wittekindt C, Würdemann N, Sharma SJ, Gattenlöhner S, Klussmann JP, von Buchwald C (2019a) Impact on survival of tobacco smoking for cases with oropharyngeal squamous cell carcinoma and known human papillomavirus and p16-status: a multicenter retrospective study. Oncotarget 10: 4655–4663
        doi: 10.18632/oncotarget.27079

    64. Grønhøj C, Kronberg Jakobsen K, Kjær E, Friborg J, von Buchwald C (2019b) Comorbidity in HPV+ and HPV- oropharyngeal cancer patients: a population-based, case-control study. Oral Oncol 96: 1–6
        doi: 10.1016/j.oraloncology.2019.06.035

    65. Guo T, Zambo KDA, Zamuner FT, Ou T, Hopkins C, Kelley DZ, Wulf HA, Winkler E, Erbe R, Danilova L, Considine M, Sidransky D, Favorov A, Florea L, Fertig EJ, Gaykalova DA (2020) Chromatin structure regulates cancer-specific alternative splicing events in primary HPV-related oropharyngeal squamous cell carcinoma. Epigenetics 15: 959–971
        doi: 10.1080/15592294.2020.1741757

    66. Hall SF, Griffiths RJ, O'Sullivan B, Liu FF (2019) The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting. Head Neck 41: 2271–2276
        doi: 10.1002/hed.25679

    67. Hammarstedt L, Holzhauser S, Zupancic M, Kapoulitsa F, Ursu RG, Ramqvist T, Haeggblom L, Näsman A, Dalianis T, Marklund L (2020) The value of p16 and HPV DNA in non-tonsillar, non-base of tongue oropharyngeal cancer. Acta Otolaryngol 141: 89–94

    68. Haque SU, Niu L, Kuhnell D, Hendershot J, Biesiada J, Niu W, Hagan MC, Kelsey KT, Casper KA, Wise-Draper TM, Medvedovic M, Langevin SM (2018) Differential expression and prognostic value of long non-coding RNA in HPV-negative head and neck squamous cell carcinoma. Head Neck 40: 1555–1564
        doi: 10.1002/hed.25136

    69. Hatano T, Sano D, Takahashi H, Hyakusoku H, Isono Y, Shimada S, Sawakuma K, Takada K, Oikawa R, Watanabe Y, Yamamoto H, Itoh F, Myers JN, Oridate N (2017) Identification of human papillomavirus (HPV) 16 DNA integration and the ensuing patterns of methylation in HPV-associated head and neck squamous cell carcinoma cell lines. Int J Cancer 140: 1571–1580
        doi: 10.1002/ijc.30589

    70. Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR (2014) APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 7: 1833–1841
        doi: 10.1016/j.celrep.2014.05.012

    71. Huang SH, O'Sullivan B, Su J, Ringash J, Bratman SV, Kim J, Hosni A, Bayley A, Cho J, Giuliani M, Hope A, Spreafico A, Hansen AR, Siu LL, Gilbert R, Irish JC, Goldstein D, de Almeida J, Tong L, Xu W, Waldron J (2020) Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: the Princess Margaret experience and proposal. Cancer 126: 3426–3437

    72. Huebbers CU, Verhees F, Poluschkin L, Olthof NC, Kolligs J, Siefer OG, Henfling M, Ramaekers FCS, Preuss SF, Beutner D, Seehawer J, Drebber U, Korkmaz Y, Lam WL, Vucic EA, Kremer B, Klussmann JP, Speel EM (2019) Upregulation of AKR1C1 and AKR1C3 expression in OPSCC with integrated HPV16 and HPV-negative tumors is an indicator of poor prognosis. Int J Cancer 144: 2465–2477
        doi: 10.1002/ijc.31954

    73. Jamieson LM, Antonsson A, Garvey G, Ju X, Smith M, Logan RM, Johnson NW, Hedges J, Sethi S, Dunbar T, Leane C, Hill I, Brown A, Roder D, De Souza M, Canfell K (2020) Prevalence of oral human papillomavirus infection among australian indigenous adults. JAMA Netw Open 3: e204951
        doi: 10.1001/jamanetworkopen.2020.4951

    74. Joseph AW, Ogawa T, Bishop JA, Lyford-Pike S, Chang X, Phelps TH, Westra WH, Pai SI (2013) Molecular etiology of second primary tumors in contralateral tonsils of human papillomavirus-associated index tonsillar carcinomas. Oral Oncol 49: 244–248
        doi: 10.1016/j.oraloncology.2012.09.009

    75. Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, Rozen SG, Salgia R, Weichselbaum RR, Lingen MW, Story MD, Ang KK, Cohen EE, White KP, Vokes EE, Seiwert TY (2015) Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res 21: 870–881
        doi: 10.1158/1078-0432.CCR-14-2481

    76. Kerr DA, Arora KS, Mahadevan KK, Hornick JL, Krane JF, Rivera MN, Ting DT, Deshpande V, Faquin WC (2015) Performance of a branch chain RNA In Situ hybridization assay for the detection of high-risk human papillomavirus in head and neck squamous cell carcinoma. Am J Surg Pathol 39: 1643–1652
        doi: 10.1097/PAS.0000000000000516

    77. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89: 12180–12184
        doi: 10.1073/pnas.89.24.12180

    78. Kofler B, Borena W, Dudas J, Innerhofer V, Dejaco D, Steinbichler TB, Widmann G, von Laer D, Riechelmann H (2020) Post-treatment HPV surface brushings and risk of relapse in oropharyngeal carcinoma. Cancers (basel) 12: 1069
        doi: 10.3390/cancers12051069

    79. Kondo S, Wakae K, Wakisaka N, Nakanishi Y, Ishikawa K, Komori T, Moriyama-Kita M, Endo K, Murono S, Wang Z, Kitamura K, Nishiyama T, Yamaguchi K, Shigenobu S, Muramatsu M, Yoshizaki T (2017) APOBEC3A associates with human papillomavirus genome integration in oropharyngeal cancers. Oncogene 36: 1687–1697
        doi: 10.1038/onc.2016.335

    80. Koneva LA, Zhang Y, Virani S, Hall PB, McHugh JB, Chepeha DB, Wolf GT, Carey TE, Rozek LS, Sartor MA (2018) HPV integration in HNSCC correlates with survival outcomes, immune response signatures, and candidate drivers. Mol Cancer Res 16: 90–102
        doi: 10.1158/1541-7786.MCR-17-0153

    81. Kopczyńska M, Kolenda T, Guglas K, Sobocińska J, Teresiak A, Bliźniak R, Mackiewicz A, Mackiewicz J, Lamperska K (2020) PRINS lncRNA Is a new biomarker candidate for HPV infection and prognosis of head and neck squamous cell carcinomas. Diagnostics (basel) 10: 762
        doi: 10.3390/diagnostics10100762

    82. Kostareli E, Hielscher T, Zucknick M, Baboci L, Wichmann G, Holzinger D, Mücke O, Pawlita M, Del Mistro A, Boscolo-Rizzo P, Da Mosto MC, Tirelli G, Plinkert P, Dietz A, Plass C, Weichenhan D, Hess J (2016) Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients. Epigenetics 11: 61–73
        doi: 10.1080/15592294.2015.1137414

    83. Kostareli E, Holzinger D, Bogatyrova O, Hielscher T, Wichmann G, Keck M, Lahrmann B, Grabe N, Flechtenmacher C, Schmidt CR, Seiwert T, Dyckhoff G, Dietz A, Höfler D, Pawlita M, Benner A, Bosch FX, Plinkert P, Plass C, Weichenhan D, Hess J (2013) HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. J Clin Invest 123: 2488–2501
        doi: 10.1172/JCI67010

    84. Krishna S, Ulrich P, Wilson E, Parikh F, Narang P, Yang S, Read AK, Kim-Schulze S, Park JG, Posner M, Wilson Sayres MA, Sikora A, Anderson KS (2018) Human papilloma virus specific immunogenicity and dysfunction of CD8(+) T cells in head and neck cancer. Cancer Res 78: 6159–6170
        doi: 10.1158/0008-5472.CAN-18-0163

    85. Kwon S, Ahn SH, Jeong WJ, Jung YH, Bae YJ, Paik JH, Chung JH, Kim H (2020) Estrogen receptor α as a predictive biomarker for survival in human papillomavirus-positive oropharyngeal squamous cell carcinoma. J Transl Med 18: 240
        doi: 10.1186/s12967-020-02396-8

    86. Lang Kuhs KA, Kreimer AR, Trivedi S, Holzinger D, Pawlita M, Pfeiffer RM, Gibson SP, Schmitt NC, Hildesheim A, Waterboer T, Ferris RL (2017) Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence. Cancer 123: 4382–4390
        doi: 10.1002/cncr.30966

    87. Law EK, Levin-Klein R, Jarvis MC, Kim H, Argyris PP, Carpenter MA, Starrett GJ, Temiz NA, Larson LK, Durfee C, Burns MB, Vogel RI, Stavrou S, Aguilera AN, Wagner S, Largaespada DA, Starr TK, Ross SR, Harris RS (2020) APOBEC3A catalyzes mutation and drives carcinogenesis in vivo. J Exp Med 217: e20200261
        doi: 10.1084/jem.20200261

    88. Leemans CR, Snijders PJF, Brakenhoff RH (2018) The molecular landscape of head and neck cancer. Nat Rev Cancer 18: 269–282
        doi: 10.1038/nrc.2018.11

    89. Lesseur C, Diergaarde B, Olshan AF, Wünsch-Filho V, Ness AR, Liu G, Lacko M, Eluf-Neto J, Franceschi S, Lagiou P, Macfarlane GJ, Richiardi L, Boccia S, Polesel J, Kjaerheim K, Zaridze D, Johansson M, Menezes AM, Curado MP, Robinson M, Ahrens W, Canova C, Znaor A, Castellsagué X, Conway DI, Holcátová I, Mates D, Vilensky M, Healy CM, Szeszenia-Dąbrowska N, Fabiánová E, Lissowska J, Grandis JR, Weissler MC, Tajara EH, Nunes FD, de Carvalho MB, Thomas S, Hung RJ, Peters WH, Herrero R, Cadoni G, Bueno-de-Mesquita HB, Steffen A, Agudo A, Shangina O, Xiao X, Gaborieau V, Chabrier A, Anantharaman D, Boffetta P, Amos CI, McKay JD, Brennan P (2016) Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. Nat Genet 48: 1544–1550
        doi: 10.1038/ng.3685

    90. Lewis JS Jr (2020) Human papillomavirus testing in head and neck squamous cell carcinoma in 2020: where are we now and where are we going? Head Neck Pathol 14: 321–329
        doi: 10.1007/s12105-019-01117-y

    91. Lewis JS Jr, Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, Moncur JT, Rocco JW, Schwartz MR, Seethala RR, Thomas NE, Westra WH, Faquin WC (2018) Human papillomavirus testing in head and neck carcinomas: guideline from the college of American pathologists. Arch Pathol Lab Med 142: 559–597
        doi: 10.5858/arpa.2017-0286-CP

    92. Lindsay CD, Kostiuk MA, Harris J, O'Connell DA, Seikaly H, Biron VL (2017) Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas. Clin Epigenetics 9: 95
        doi: 10.1186/s13148-017-0390-y

    93. Liu H, Xu J, Yang Y, Wang X, Wu E, Majerciak V, Zhang T, Steenbergen RDM, Wang HK, Banerjee NS, Li Y, Lu W, Meyers C, Zhu J, Xie X, Chow LT, Zheng ZM (2021) Oncogenic HPV promotes the expression of the long noncoding RNA lnc-FANCI-2 through E7 and YY1. Proc Natl Acad Sci U S A 118: e2014195118
        doi: 10.1073/pnas.2014195118

    94. Liu J, Yang XL, Zhang SW, Zhu LP, Chen WQ (2018) Incidence, mortality, and temporal patterns of oropharyngeal cancer in China: a population-based study. Cancer Commun (lond) 38: 75
        doi: 10.1186/s40880-018-0345-5

    95. Liu X, Liu P, Chernock RD, Kuhs KAL, Lewis JS Jr, Luo J, Gay HA, Thorstad WL, Wang X (2020) A prognostic gene expression signature for oropharyngeal squamous cell carcinoma. EBioMedicine 61: 102805
        doi: 10.1016/j.ebiom.2020.102805

    96. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR (2013) Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3: 761–769
        doi: 10.1158/2159-8290.CD-13-0103

    97. Luo M, Wang H, Wang Z, Cai H, Lu Z, Li Y, Du M, Huang G, Wang C, Chen X, Porembka MR, Lea J, Frankel AE, Fu YX, Chen ZJ, Gao J (2017) A STING-activating nanovaccine for cancer immunotherapy. Nat Nanotechnol 12: 648–654
        doi: 10.1038/nnano.2017.52

    98. Luo X, Donnelly CR, Gong W, Heath BR, Hao Y, Donnelly LA, Moghbeli T, Tan YS, Lin X, Bellile E, Kansy BA, Carey TE, Brenner JC, Cheng L, Polverini PJ, Morgan MA, Wen H, Prince ME, Ferris RL, Xie Y, Young S, Wolf GT, Chen Q, Lei YL (2020) HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. J Clin Invest 130: 1635–1652
        doi: 10.1172/JCI129497

    99. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA, Chen L, Drake CG, Topalian SL, Pardoll DM, Pai SI (2013) Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 73: 1733–1741
        doi: 10.1158/0008-5472.CAN-12-2384

    100. Lyu X, Zhang M, Li G, Jiang Y, Qiao Q (2019) PD-1 and PD-L1 expression predicts radiosensitivity and clinical outcomes in head and neck cancer and is associated with HPV infection. J Cancer 10: 937–948
        doi: 10.7150/jca.27199

    101. Mac M, Moody CA (2020) Epigenetic regulation of the human papillomavirus life cycle. Pathogens 9: 483
        doi: 10.3390/pathogens9060483

    102. Madathil S, Rousseau MC, Joseph L, Coutlée F, Schlecht NF, Franco E, Nicolau B (2020) Latency of tobacco smoking for head and neck cancer among HPV-positive and HPV-negative individuals. Int J Cancer 147: 56–64
        doi: 10.1002/ijc.32708

    103. Marquard FE, Jücker M (2020) PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochem Pharmacol 172: 113729
        doi: 10.1016/j.bcp.2019.113729

    104. Massarelli E, William W, Johnson F, Kies M, Ferrarotto R, Guo M, Feng L, Lee JJ, Tran H, Kim YU, Haymaker C, Bernatchez C, Curran M, Zecchini Barrese T, Rodriguez Canales J, Wistuba I, Li L, Wang J, van der Burg SH, Melief CJ, Glisson B (2019) Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncol 5: 67–73
        doi: 10.1001/jamaoncol.2018.4051

    105. McLaughlin-Drubin ME, Park D, Munger K (2013) Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines. Proc Natl Acad Sci U S A 110: 16175–16180
        doi: 10.1073/pnas.1310432110

    106. Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393: 51–60
        doi: 10.1016/S0140-6736(18)32752-1

    107. Mesri EA, Feitelson MA, Munger K (2014) Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 15: 266–282
        doi: 10.1016/j.chom.2014.02.011

    108. Mezache L, Paniccia B, Nyinawabera A, Nuovo GJ (2015) Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol 28: 1594–1602
        doi: 10.1038/modpathol.2015.108

    109. Mifsud M, Eskander A, Irish J, Gullane P, Gilbert R, Brown D, de Almeida JR, Urbach DR, Goldstein DP (2017) Evolving trends in head and neck cancer epidemiology: Ontario, Canada 1993–2010. Head Neck 39: 1770–1778
        doi: 10.1002/hed.24829

    110. Miyauchi S, Sanders PD, Guram K, Kim SS, Paolini F, Venuti A, Cohen EEW, Gutkind JS, Califano JA, Sharabi AB (2020) HPV16 E5 mediates resistance to PD-L1 blockade and can be targeted with rimantadine in head and neck cancer. Cancer Res 80: 732–746
        doi: 10.1158/0008-5472.CAN-19-1771

    111. Molony P, Werner R, Martin C, Callanan D, Nauta I, Heideman D, Sheahan P, Heffron C, Feeley L (2020) The role of tumour morphology in assigning HPV status in oropharyngeal squamous cell carcinoma. Oral Oncol 105: 104670
        doi: 10.1016/j.oraloncology.2020.104670

    112. Mourad M, Jetmore T, Jategaonkar AA, Moubayed S, Moshier E, Urken ML (2017) Epidemiological Trends Of Head And Neck Cancer in the United States: A SEER population study. J Oral Maxillofac Surg 75: 2562–2572
        doi: 10.1016/j.joms.2017.05.008

    113. Mroz EA, Tward AD, Pickering CR, Myers JN, Ferris RL, Rocco JW (2013) High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer 119: 3034–3042
        doi: 10.1002/cncr.28150

    114. Ni G, Huang K, Luan Y, Cao Z, Chen S, Ma B, Yuan J, Wu X, Chen G, Wang T, Li H, Walton S, Liu F, Chen B, Wang Y, Pan X, Liu X, Frazer IH (2019) Human papillomavirus infection among head and neck squamous cell carcinomas in southern China. PLoS One 14: e0221045
        doi: 10.1371/journal.pone.022104506|2008|||

    115. Nohata N, Abba MC, Gutkind JS (2016) Unraveling the oral cancer lncRNAome: Identification of novel lncRNAs associated with malignant progression and HPV infection. Oral Oncol 59: 58–66
        doi: 10.1016/j.oraloncology.2016.05.014

    116. Nopmaneepaisarn T, Tangjaturonrasme N, Rawangban W, Vinayanuwattikun C, Keelawat S, Bychkov A (2019) Low prevalence of p16-positive HPV-related head-neck cancers in Thailand: tertiary referral center experience. BMC Cancer 19: 1050
        doi: 10.1186/s12885-019-6266-0

    117. Olthof NC, Huebbers CU, Kolligs J, Henfling M, Ramaekers FC, Cornet I, van Lent-Albrechts JA, Stegmann AP, Silling S, Wieland U, Carey TE, Walline HM, Gollin SM, Hoffmann TK, de Winter J, Kremer B, Klussmann JP, Speel EJ (2015) Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines. Int J Cancer 136: E207-218
        doi: 10.1002/ijc.29112

    118. Olthof NC, Speel EJ, Kolligs J, Haesevoets A, Henfling M, Ramaekers FC, Preuss SF, Drebber U, Wieland U, Silling S, Lam WL, Vucic EA, Kremer B, Klussmann JP, Huebbers CU (2014) Comprehensive analysis of HPV16 integration in OSCC reveals no significant impact of physical status on viral oncogene and virally disrupted human gene expression. PLoS ONE 9: e88718
        doi: 10.1371/journal.pone.0088718

    119. Outh-Gauer S, Morini A, Tartour E, Lépine C, Jung AC, Badoual C (2020) The microenvironment of head and neck cancers: papillomavirus involvement and potential impact of immunomodulatory treatments. Head Neck Pathol 14: 330–340
        doi: 10.1007/s12105-020-01147-x

    120. Pal A, Kundu R (2019) Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Front Microbiol 10: 3116

    121. Papillon-Cavanagh S, Lu C, Gayden T, Mikael LG, Bechet D, Karamboulas C, Ailles L, Karamchandani J, Marchione DM, Garcia BA, Weinreb I, Goldstein D, Lewis PW, Dancu OM, Dhaliwal S, Stecho W, Howlett CJ, Mymryk JS, Barrett JW, Nichols AC, Allis CD, Majewski J, Jabado N (2017) Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas. Nat Genet 49: 180–185
        doi: 10.1038/ng.3757

    122. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R (2014) Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A 111: 15544–15549
        doi: 10.1073/pnas.1416074111

    123. Parikh F, Duluc D, Imai N, Clark A, Misiukiewicz K, Bonomi M, Gupta V, Patsias A, Parides M, Demicco EG, Zhang DY, Kim-Schulze S, Kao J, Gnjatic S, Oh S, Posner MR, Sikora AG (2014) Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. Cancer Res 74: 7205–7216
        doi: 10.1158/0008-5472.CAN-14-1913

    124. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, Zhao M, Ortega Alves MV, Chang K, Drummond J, Cortez E, Xie TX, Zhang D, Chung W, Issa JP, Zweidler-McKay PA, Wu X, El-Naggar AK, Weinstein JN, Wang J, Muzny DM, Gibbs RA, Wheeler DA, Myers JN, Frederick MJ (2013) Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 3: 770–781
        doi: 10.1158/2159-8290.CD-12-0537

    125. Pim D, Massimi P, Dilworth SM, Banks L (2005) Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene 24: 7830–7838
        doi: 10.1038/sj.onc.1208935

    126. Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, Rodman C, Luo CL, Mroz EA, Emerick KS, Deschler DG, Varvares MA, Mylvaganam R, Rozenblatt-Rosen O, Rocco JW, Faquin WC, Lin DT, Regev A, Bernstein BE (2017) Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171: 1611-1624. e1624
        doi: 10.1016/j.cell.2017.10.044

    127. Qi Z, Barrett T, Parikh AS, Tirosh I, Puram SV (2019) Single-cell sequencing and its applications in head and neck cancer. Oral Oncol 99: 104441
        doi: 10.1016/j.oraloncology.2019.104441

    128. Qian X, Kaufmann AM, Chen C, Tzamalis G, Hofmann VM, Keilholz U, Hummel M, Albers AE (2016) Prevalence and associated survival of high-risk HPV-related adenoid cystic carcinoma of the salivary glands. Int J Oncol 49: 803–811
        doi: 10.3892/ijo.2016.3563

    129. Qian X, Leonard F, Wenhao Y, Sudhoff H, Hoffmann TK, Ferrone S, Kaufmann AM, Albers AE (2020) Immunotherapeutics for head and neck squamous cell carcinoma stem cells. HNO 68: 94–99
        doi: 10.1007/s00106-020-00819-y

    130. Qian X, Nguyen DT, Dong Y, Sinikovic B, Kaufmann AM, Myers JN, Albers AE, Graviss EA (2019) Prognostic score predicts survival in HPV-negative head and neck squamous cell cancer patients. Int J Biol Sci 15: 1336–1344
        doi: 10.7150/ijbs.33329

    131. Qin Y, Ekmekcioglu S, Forget MA, Szekvolgyi L, Hwu P, Grimm EA, Jazaeri AA, Roszik J (2017) Cervical cancer neoantigen landscape and immune activity is associated with human papillomavirus master regulators. Front Immunol 8: 689
        doi: 10.3389/fimmu.2017.00689

    132. Rasmussen JH, Grønhøj C, Håkansson K, Friborg J, Andersen E, Lelkaitis G, Klussmann JP, Wittekindt C, Wagner S, Vogelius IR, von Buchwald C (2019) Risk profiling based on p16 and HPV DNA more accurately predicts location of disease relapse in patients with oropharyngeal squamous cell carcinoma. Ann Oncol 30: 629–636
        doi: 10.1093/annonc/mdz010

    133. Ravanelli M, Grammatica A, Maddalo M, Ramanzin M, Agazzi GM, Tononcelli E, Battocchio S, Bossi P, Vezzoli M, Maroldi R, Farina D (2020) Pretreatment DWI with histogram analysis of the ADC in predicting the outcome of advanced oropharyngeal cancer with known human papillomavirus status treated with chemoradiation. AJNR Am J Neuroradiol 41: 1473–1479
        doi: 10.3174/ajnr.A6695

    134. Reid P, Marcu LG, Olver I, Moghaddasi L, Staudacher AH, Bezak E (2019) Diversity of cancer stem cells in head and neck carcinomas: the role of HPV in cancer stem cell heterogeneity, plasticity and treatment response. Radiother Oncol 135: 1–12
        doi: 10.1016/j.radonc.2019.02.016

    135. Ren J, Yang W, Su J, Ren X, Fazelzad R, Albert T, Habbous S, Goldstein DP, de Almeida JR, Hansen A, Jang R, Bratman SV, Hope A, Chen R, Wang J, Xu Y, Cheng D, Zhao Y, Xu W, Liu G (2019) Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region. Int J Cancer 145: 1465–1474
        doi: 10.1002/ijc.32164

    136. Ren S, Gaykalova D, Wang J, Guo T, Danilova L, Favorov A, Fertig E, Bishop J, Khan Z, Flam E, Wysocki PT, DeJong P, Ando M, Liu C, Sakai A, Fukusumi T, Haft S, Sadat S, Califano JA (2018) Discovery and development of differentially methylated regions in human papillomavirus-related oropharyngeal squamous cell carcinoma. Int J Cancer 143: 2425–2436
        doi: 10.1002/ijc.31778

    137. Rettig EM, Gooi Z, Bardin R, Bogale M, Rooper L, Acha E, Koch WM (2019) Oral Human Papillomavirus Infection and Head and Neck Squamous Cell Carcinoma in Rural Northwest Cameroon. OTO Open 3: 2473974x18818415

    138. Roman A, Munger K (2013) The papillomavirus E7 proteins. Virology 445: 138–168
        doi: 10.1016/j.virol.2013.04.013

    139. Rotsides JM, Oliver JR, Moses LE, Tam M, Li Z, Schreiber D, Jacobson AS, Hu KS, Givi B (2020) Socioeconomic and racial disparities and survival of human papillomavirus-associated oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg 164: 131–138

    140. Ruicci KM, Meens J, Plantinga P, Stecho W, Pinto N, Yoo J, Fung K, MacNeil D, Mymryk JS, Barrett JW, Howlett CJ, Boutros PC, Ailles L, Nichols AC (2020) TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma. J Exp Clin Cancer Res 39: 217
        doi: 10.1186/s13046-020-01713-9

    141. Ruicci KM, Meens J, Sun RX, Rizzo G, Pinto N, Yoo J, Fung K, MacNeil D, Mymryk JS, Barrett JW, Boutros PC, Ailles L, Nichols AC (2019a) A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth. Int J Cancer 145: 2100–2106
        doi: 10.1002/ijc.32009

    142. Ruicci KM, Plantinga P, Pinto N, Khan MI, Stecho W, Dhaliwal SS, Yoo J, Fung K, MacNeil D, Mymryk JS, Barrett JW, Howlett CJ, Nichols AC (2019b) Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition. Mol Oncol 13: 2160–2177
        doi: 10.1002/1878-0261.12558

    143. Schiller JT, Castellsagué X, Garland SM (2012) A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30(Suppl 5): F123-138

    144. Schroeder L, Pring M, Ingarfield K, Pawlita M, Leary SD, Thomas SJ, Waylen A, Waterboer T, Ness AR (2020) HPV driven squamous cell head and neck cancer of unknown primary is likely to be HPV driven squamous cell oropharyngeal cancer. Oral Oncol 107: 104721
        doi: 10.1016/j.oraloncology.2020.104721

    145. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17: 956–965
        doi: 10.1016/S1470-2045(16)30066-3

    146. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168: 707–723
        doi: 10.1016/j.cell.2017.01.017

    147. Shen S, Saito Y, Ren S, Liu C, Guo T, Qualliotine J, Khan Z, Sadat S, Califano JA (2020) Targeting viral DNA and promoter hypermethylation in salivary rinses for recurrent HPV-positive oropharyngeal cancer. Otolaryngol Head Neck Surg 162: 512–519
        doi: 10.1177/0194599820903031

    148. Sievert M, Goncalves M, Mueller SK, Hecht M, Pflaum A, Grundtner P, Iro H, Gostian AO (2020) Impact of delayed adjuvant therapy after surgery in p16 positive oropharyngeal cancer: a retrospective analysis. Eur Rev Med Pharmacol Sci 24: 1211–1218

    149. Smith EM, Pawlita M, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP (2010) Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int J Cancer 127: 111–117
        doi: 10.1002/ijc.25015

    150. Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D, Haugen TH, Turek LP (2004) Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 108: 766–772
        doi: 10.1002/ijc.11633

    151. Song L, Xie H, Tong F, Yan B, Zhang S, Fu E, Jing Q, Wei L (2019) Association of lnc-IL17RA-11 with increased radiation sensitivity and improved prognosis of HPV-positive HNSCC. J Cell Biochem 120: 17438–17448
        doi: 10.1002/jcb.29008

    152. Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, Hinrichs CS (2017) Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science 356: 200–205
        doi: 10.1126/science.aak9510

    153. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157–1160
        doi: 10.1126/science.1208130

    154. Strober W, Shishido S, Wood B, Lewis JS Jr, Kuhs K, Ferris RL, Faden DL (2020) Two for the price of one: prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck Cancers. Oral Oncol 100: 104475
        doi: 10.1016/j.oraloncology.2019.104475

    155. Suh CH, Lee KH, Choi YJ, Chung SR, Baek JH, Lee JH, Yun J, Ham S, Kim N (2020) Oropharyngeal squamous cell carcinoma: radiomic machine-learning classifiers from multiparametric MR images for determination of HPV infection status. Sci Rep 10: 17525
        doi: 10.1038/s41598-020-74479-x

    156. Surviladze Z, Sterk RT, DeHaro SA, Ozbun MA (2013) Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy. J Virol 87: 2508–2517
        doi: 10.1128/JVI.02319-12

    157. Tang KD, Vasani S, Menezes L, Taheri T, Walsh LJ, Hughes BGM, Frazer IH, Kenny L, Scheper GC, Punyadeera C (2020) Oral HPV16 DNA as a screening tool to detect early oropharyngeal squamous cell carcinoma. Cancer Sci 111: 3854–3861
        doi: 10.1111/cas.14585

    158. Tang S, Tao M, McCoy JP Jr, Zheng ZM (2006) The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. J Virol 80: 4249–4263
        doi: 10.1128/JVI.80.9.4249-4263.2006

    159. The Cancer Genome Atlas Network (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517: 576–582
        doi: 10.1038/nature14129

    160. Tinhofer I, Jöhrens K, Keilholz U, Kaufmann A, Lehmann A, Weichert W, Stenzinger A, Stromberger C, Klinghammer K, Becker ET, Dommerich S, Stölzel K, Hofmann VM, Hildebrandt B, Moser L, Ervens J, Böttcher A, Albers A, Stabenow R, Reinecke A, Budach V, Hoffmeister B, Raguse JD (2015) Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence. Eur J Cancer 51: 514–521
        doi: 10.1016/j.ejca.2014.12.018

    161. Tumban E (2019) A current update on human papillomavirus-associated head and neck cancers. Viruses 11: 922
        doi: 10.3390/v11100922

    162. Vande Pol SB, Klingelhutz AJ (2013) Papillomavirus E6 oncoproteins. Virology 445: 115–137
        doi: 10.1016/j.virol.2013.04.026

    163. Ventz S, Trippa L, Schoenfeld JD (2019) Lessons learned from deescalation trials in favorable risk HPV-associated squamous cell head and neck cancer-a perspective on future trial designs. Clin Cancer Res 25: 7281–7286
        doi: 10.1158/1078-0432.CCR-19-0945

    164. Viros Porcuna D, Pollan Guisasola C, Viña Soria C, Cirauqui Cirauqui B, Pardo Muñoz L, Collurá F, Mesia Nin R (2020) Transoral robotic surgery for squamous cell carcinoma of the oropharynx in a primarily human papillomavirus-negative patient population. Clin Transl Oncol 22: 1303–1311
        doi: 10.1007/s12094-019-02256-y

    165. Wagner S, Prigge ES, Wuerdemann N, Reder H, Bushnak A, Sharma SJ, Obermueller T, von Knebel DM, Dreyer T, Gattenlöhner S, Wolf G, Pons-Kühnemann J, Wittekindt C, Klussmann JP (2020) Evaluation of p16(INK4a) expression as a single marker to select patients with HPV-driven oropharyngeal cancers for treatment de-escalation. Br J Cancer 123: 1114–1122
        doi: 10.1038/s41416-020-0964-x

    166. Wakabayashi R, Nakahama Y, Nguyen V, Espinoza JL (2019) The Host-Microbe Interplay in Human Papillomavirus-Induced Carcinogenesis. Microorganisms 7: 199
        doi: 10.3390/microorganisms7070199

    167. Wallace NA, Münger K (2018) The curious case of APOBEC3 activation by cancer-associated human papillomaviruses. PLoS Pathog 14: e1006717
        doi: 10.1371/journal.ppat.1006717

    168. Walline HM, Komarck CM, McHugh JB, Bellile EL, Brenner JC, Prince ME, McKean EL, Chepeha DB, Wolf GT, Worden FP, Bradford CR, Carey TE (2016) Genomic integration of high-risk HPV alters gene expression in oropharyngeal squamous cell carcinoma. Mol Cancer Res 14: 941–952
        doi: 10.1158/1541-7786.MCR-16-0105

    169. Wang X, Liu H, Ge H, Ajiro M, Sharma NR, Meyers C, Morozov P, Tuschl T, Klar A, Court D, Zheng ZM (2017) Viral DNA replication orientation and hnRNPs regulate transcription of the human papillomavirus 18 late promoter. Mbio 8: e00713–e00717
        doi: 10.1128/mBio.00713-17

    170. Wang X, Meyers C, Wang HK, Chow LT, Zheng ZM (2011) Construction of a full transcription map of human papillomavirus type 18 during productive viral infection. J Virol 85: 8080–8092
        doi: 10.1128/JVI.00670-11

    171. Wang X, Wang HK, Li Y, Hafner M, Banerjee NS, Tang S, Briskin D, Meyers C, Chow LT, Xie X, Tuschl T, Zheng ZM (2014) microRNAs are biomarkers of oncogenic human papillomavirus infections. Proc Natl Acad Sci U S A 111: 4262–4267
        doi: 10.1073/pnas.1401430111

    172. Ward MJ, Thirdborough SM, Mellows T, Riley C, Harris S, Suchak K, Webb A, Hampton C, Patel NN, Randall CJ, Cox HJ, Jogai S, Primrose J, Piper K, Ottensmeier CH, King EV, Thomas GJ (2014) Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer 110: 489–500
        doi: 10.1038/bjc.2013.639

    173. Weiss BG, Anczykowski MZ, Küffer S, Spiegel JL, Bertlich M, Canis M, Ihler F, Kitz J, Jakob M (2020) Prognostic impact of additional HPV diagnostics in 102 patients with p16-stratified advanced oropharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol Undefined: https://doi.org/10.1007/s00405-020-06262-7
        doi: 10.1007/s00405-020-06262-7

    174. Welters MJP, Ma W, Santegoets S, Goedemans R, Ehsan I, Jordanova ES, van Ham VJ, van Unen V, Koning F, van Egmond SI, Charoentong P, Trajanoski Z, van der Velden LA, van der Burg SH (2018) Intratumoral HPV16-specific T cells constitute a type Ⅰ-oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer. Clin Cancer Res 24: 634–647
        doi: 10.1158/1078-0432.CCR-17-2140

    175. White R, Abel S, Hasan S, Verma V, Greenberg L, Colonias A, Wegner RE (2020) Practice patterns and outcomes following radiation dose de-escalation for oropharyngeal cancer. Laryngoscope 130: E171-e176
        doi: 10.1002/lary.27897

    176. Wichmann G, Rosolowski M, Krohn K, Kreuz M, Boehm A, Reiche A, Scharrer U, Halama D, Bertolini J, Bauer U, Holzinger D, Pawlita M, Hess J, Engel C, Hasenclever D, Scholz M, Ahnert P, Kirsten H, Hemprich A, Wittekind C, Herbarth O, Horn F, Dietz A, Loeffler M (2015) The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. Int J Cancer 137: 2846–2857
        doi: 10.1002/ijc.29649

    177. Wiegand S, Wichmann G, Golusinski W, Leemans CR, Klussmann JP, Dietz A (2018) Highlights from the Second International Symposium on HPV infection in head and neck cancer. Eur Arch Otorhinolaryngol 275: 1365–1373
        doi: 10.1007/s00405-018-4954-z

    178. Wieland A, Patel MR, Cardenas MA, Eberhardt CS, Hudson WH, Obeng RC, Griffith CC, Wang X, Chen ZG, Kissick HT, Saba NF, Ahmed R (2020) Defining HPV-specific B cell responses in patients with head and neck cancer. Nature Undefined: https://doi.org/10.1038/s41586-020-2931-3
        doi: 10.1038/s41586-020-2931-3

    179. Wittekindt C, Wagner S, Bushnak A, Prigge ES, von Knebel DM, Würdemann N, Bernhardt K, Pons-Kühnemann J, Maulbecker-Armstrong C, Klussmann JP (2019) Increasing incidence rates of oropharyngeal squamous cell carcinoma in germany and significance of disease burden attributed to human papillomavirus. Cancer Prev Res (phila) 12: 375–382
        doi: 10.1158/1940-6207.CAPR-19-0098

    180. Wittekindt C, Wagner S, Sharma SJ, Würdemann N, Knuth J, Reder H, Klußmann JP (2018) HPV - a different view on Head and Neck Cancer. Laryngorhinootologie 97: S48-s113
        doi: 10.1055/s-0043-121596

    181. Xu Q, Fang M, Zhu J, Dong H, Cao J, Yan L, Leonard F, Oppel F, Sudhoff H, Kaufmann AM, Albers AE, Qian X (2020a) Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck. Int J Biol Sci 16: 2506–2517
        doi: 10.7150/ijbs.47068

    182. Xu S, Sun B, Zhou R, Shi C, Han Y, Li J, Sun J, Tian Z, Zhang Z, Li J (2020b) Evaluation of p16 as a surrogate marker for transcriptionally active human papillomavirus status of oropharyngeal squamous cell carcinoma in an eastern Chinese population. Oral Surg Oral Med Oral Pathol Oral Radiol 129: 236-245. e232
        doi: 10.1016/j.oooo.2019.11.008

    183. Xu T, Shen C, Wei Y, Hu C, Wang Y, Xiang J, Sun GH, Su F, Wang Q, Lu X (2020c) Human papillomavirus (HPV) in Chinese oropharyngeal squamous cell carcinoma (OPSCC): a strong predilection for the tonsil. Cancer Med 9: 6556–6564
        doi: 10.1002/cam4.3339

    184. Xue XY, Majerciak V, Uberoi A, Kim BH, Gotte D, Chen X, Cam M, Lambert PF, Zheng ZM (2017) The full transcription map of mouse papillomavirus type 1 (MmuPV1) in mouse wart tissues. PLoS Pathog 13: e1006715
        doi: 10.1371/journal.ppat.1006715

    185. Yang JQ, Wu M, Han FY, Sun YM, Zhang L, Liu HX (2020) High risk HPV detection by RNAscope in situ hybridization combined with Cdc2 protein expression by immunohistochemistry for prognosis of oropharyngeal squamous cell carcinoma. Int J Clin Exp Pathol 13: 2192–2200

    186. Yang W, Lu YP, Yang YZ, Kang JR, Jin YD, Wang HW (2017) Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. J Obstet Gynaecol Res 43: 1602–1612
        doi: 10.1111/jog.13411

    187. Yang W, Song Y, Lu YL, Sun JZ, Wang HW (2013) Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology 139: 513–522
        doi: 10.1111/imm.12101

    188. Young RJ, Bressel M, Porceddu S, Cernelc J, Savas P, Liu H, Urban D, Thai AA, Cooper C, Fua T, Neeson P, Rischin D, Solomon B (2020a) Validation and characterisation of prognostically significant PD-L1(+) immune cells in HPV+ oropharyngeal squamous cell carcinoma. Oral Oncol 101: 104516
        doi: 10.1016/j.oraloncology.2019.104516

    189. Young RJ, Solomon B, Corry J, Angel C, Kenny L, Porceddu S, Wratten C, Macann A, Jackson JE, Herschtal A, Rischin D (2020b) Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial - A Trans-Tasman Radiation Oncology Group study. Oral Oncol 110: 104988
        doi: 10.1016/j.oraloncology.2020.104988

    190. Zamani M, Grønhøj C, Jensen DH, Carlander AF, Agander T, Kiss K, Olsen C, Baandrup L, Nielsen FC, Andersen E, Friborg J, von Buchwald C (2020) The current epidemic of HPV-associated oropharyngeal cancer: an 18-year Danish population-based study with 2, 169 patients. Eur J Cancer 134: 52–59
        doi: 10.1016/j.ejca.2020.04.027

    191. Zapatka M, Borozan I, Brewer DS, Iskar M, Grundhoff A, Alawi M, Desai N, Sültmann H, Moch H, Cooper CS, Eils R, Ferretti V, Lichter P (2020) The landscape of viral associations in human cancers. Nat Genet 52: 320–330
        doi: 10.1038/s41588-019-0558-9

    192. Zhang J, Chen T, Yang X, Cheng H, Späth SS, Clavijo PE, Chen J, Silvin C, Issaeva N, Su X, Yarbrough WG, Annunziata CM, Chen Z, Van Waes C (2018) Attenuated TRAF3 fosters activation of alternative NF-κB and reduced expression of antiviral interferon, TP53, and RB to promote HPV-positive head and neck cancers. Cancer Res 78: 4613–4626
        doi: 10.1158/0008-5472.CAN-17-0642

    193. Zheng ZM, Baker CC (2006) Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci 11: 2286–2302
        doi: 10.2741/1971

    194. Zheng ZM, Tao M, Yamanegi K, Bodaghi S, Xiao W (2004) Splicing of a cap-proximal human Papillomavirus 16 E6E7 intron promotes E7 expression, but can be restrained by distance of the intron from its RNA 5' cap. J Mol Biol 337: 1091–1108
        doi: 10.1016/j.jmb.2004.02.023

    195. Zheng ZM, Wang X (2011) Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta 1809: 668–677
        doi: 10.1016/j.bbagrm.2011.05.005

    196. Zhou C, Tuong ZK, Frazer IH (2019) Papillomavirus immune evasion strategies target the infected cell and the local immune system. Front Oncol 9: 682
        doi: 10.3389/fonc.2019.00682

    197. Zhou G, Liu Z, Myers JN (2016) TP53 mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response. J Cell Biochem 117: 2682–2692
        doi: 10.1002/jcb.25592

    198. Zhou J, Sun XY, Stenzel DJ, Frazer IH (1991) Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185: 251–257
        doi: 10.1016/0042-6822(91)90772-4

    199. Zubair F, McMahon J, Afzali P, Cuschieri K, Swee Yan Y, Schipani S, Brands M, Ansell M (2020) Staging and treatment outcomes in oropharyngeal squamous cell carcinoma: a single-centre UK cohort. Br J Oral Maxillofac Surg 59: 28–34
        doi: 10.1016/j.bjoms.2020.07.007

  • 加载中

Figures(2) / Tables(1)

Article Metrics

Article views(8653) PDF downloads(31) Cited by()

Related
Proportional views
    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care

      Corresponding author: Xu Qian, Qian_michelle2014@163.com
    • 1. Department of Clinical Laboratory, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, 310022, China
    • 2. Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, 310022, China
    • 3. Department of Cancer Prevention, Cancer Hospital University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, 310022, China
    • 4. Clinic for Gynecology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin, 12203, Germany
    • 5. Tumor Virus RNA Biology Section, HIV Dynamics and Replication Program, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA
    • 6. Department of Otolaryngology, Head and Neck Surgery, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin, 13353, Germany

    Abstract: 

    Human papillomavirus (HPV) infection identified as a definitive human carcinogen is increasingly being recognized for its role in carcinogenesis of human cancers. Up to 38%–80% of head and neck squamous cell carcinoma (HNSCC) in oropharyngeal location (OPSCC) and nearly all cervical cancers contain the HPV genome which is implicated in causing cancer through its oncoproteins E6 and E7. Given by the biologically distinct HPV-related OPSCC and a more favorable prognosis compared to HPV-negative tumors, clinical trials on de-escalation treatment strategies for these patients have been studied. It is therefore raised the questions for the patient stratification if treatment de-escalation is feasible. Moreover, understanding the crosstalk of HPV-mediated malignancy and immunity with clinical insights from the proportional response rate to immune checkpoint blockade treatments in patients with HNSCC is of importance to substantially improve the treatment efficacy. This review discusses the biology of HPV-related HNSCC as well as successful clinically findings with promising candidates in the pipeline for future directions. With the advent of various sequencing technologies, further biomolecules associated with HPV-related HNSCC progression are currently being identified to be used as potential biomarkers or targets for clinical decisions throughout the continuum of cancer care.